Hypolipidemic effect of SIPI-7623, a derivative of an extract from oriental wormwood, through farnesoid X receptor antagonism

Deng, Yi-Fang; Huang, Xiaoling; Su, Mei; Yu, Peilin; Zhang, Zhen; Quan-hai, Liu; Wang, Guoping; Liu, Min-Yu

doi:10.1016/s1875-5364(18)30094-3

Cited by 4 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it is key to study the aforementioned signaling pathways for the development of novel treatment options and for the prevention of dyslipidemia. The majority of previous studies on signaling pathways altered by natural substances that have been proposed to treat dyslipidemia are experimental (4)(5)(6)(7)(8)(9)(10)(11). However, at present, review…”

Section: Introductionmentioning

confidence: 98%

“…Following advances in molecular biology, previous studies have demonstrated that multiple signaling pathways, including the peroxisome proliferator-activated receptor (PPAR), adenosine monophosphate-activated protein kinase (AMPK), farnesoid X receptor (FXR), forkhead box O (FOXO), adipocytokine and cyclic adenosine monophosphate (cAMP) signaling pathways, are closely associated with the occurrence and development of dyslipidemia (4)(5)(6)(7)(8)(9). Specifically, certain drugs can target specific aspects of lipid metabolism and serve a role in lowering the levels of lipids by activating or inhibiting these signaling pathways (4)(5)(6)(7)(8)(9). Therefore, it is key to study the aforementioned signaling pathways for the development of novel treatment options and for the prevention of dyslipidemia.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Research progress of signaling pathways of the natural substances intervene dyslipidemia (Review)

Cao

Wang

et al. 2022

Exp Ther Med

View full text Add to dashboard Cite

Dyslipidemia is an umbrella term for a range of lipid metabolic disorders in the body. This condition has been widely reported to greatly increase the risk of cardiovascular diseases, threatening human health. In recent years, advances in molecular biology have deepened understanding of the dyslipidemia-related signaling pathways and specific mechanisms underlying dyslipidemia. Signaling pathways possess the ability to transmit an extracellular signal to the inside of the cell, leading to specific biological effects. Lipid metabolism disorders and lipid levels in the blood are frequently affected by aberrant alterations in the dyslipidemia-related signaling pathways. Therefore, further investigations into these pathways are required for the prevention and treatment of dyslipidemia. The present review summarizes the characteristics of six dyslipidemia-associated signaling pathways: Peroxisome proliferator-activated receptor, adenosine monophosphate-activated protein kinase, farnesoid X receptor, forkhead box O, adipocytokine and cyclic adenosine monophosphate signaling pathways. In particular, specific focus was placed on previous experimental studies and reports on the intervention effects of natural substances (compounds from animals, plants, marine organisms and microorganisms) on dyslipidemia.

show abstract

Section: Introductionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Research progress of signaling pathways of the natural substances intervene dyslipidemia (Review)

Cao

Wang

et al. 2022

Exp Ther Med

View full text Add to dashboard Cite

show abstract

Structure Modification of FXR Antagonistic Chalcones and Their Inhibitory Effects on NSCLC Cell Proliferation and Metastasis

et al. 2022

View full text Add to dashboard Cite

Although the farnesoid X receptor (FXR) has been regarded as a promising drug target for metabolic diseases as well as antiinflammatory, antitumor and antiviral actions, the antagonism by FXR ligands are still underrepresented in current FXR targeted therapies. In this study, we discovered selective FXR antagonists through structure optimization from the polyoxygenated chalcone scaffold. The selective antagonist 6 p [2-methoxy-2'-hydroxy-4'-(4''-methoxy-4''-oxo-E-crotonyl) chalcone] is not only inhibitory toward non-small-cell lung cancer (NSCLC) cell proliferation in an FXR-dependent manner, but is also active in metastasis models. Taken together, this chalconebased FXR antagonist has the potential for the targeted therapy of NSCLC in which FXR is highly expressed.

show abstract

The potential of Artemisia species for use as broad-spectrum agents in the management of metabolic syndrome: a review

Ibrahim

Mukonowenzou

Usman

et al. 2021

Archives of Physiology and Biochemistry

View full text Add to dashboard Cite

Hypolipidemic effect of SIPI-7623, a derivative of an extract from oriental wormwood, through farnesoid X receptor antagonism

Cited by 4 publications

References 24 publications

Research progress of signaling pathways of the natural substances intervene dyslipidemia (Review)

Research progress of signaling pathways of the natural substances intervene dyslipidemia (Review)

Structure Modification of FXR Antagonistic Chalcones and Their Inhibitory Effects on NSCLC Cell Proliferation and Metastasis

The potential of Artemisia species for use as broad-spectrum agents in the management of metabolic syndrome: a review

Contact Info

Product

Resources

About